Compile Data Set for Download or QSAR
Report error Found 48 Enz. Inhib. hit(s) with all data for entry = 50007917
TargetIntegrin alpha-V/beta-3(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513974(CHEMBL4513624)
Affinity DataIC50: 0.794nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta3 (27 to 718 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513966(CHEMBL4468875)
Affinity DataIC50: 1.30nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta3 (27 to 718 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513976(CHEMBL4539942)
Affinity DataIC50: 2nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta3 (27 to 718 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513988(CHEMBL4445933)
Affinity DataIC50: 2nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta3 (27 to 718 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513970(CHEMBL4557585)
Affinity DataIC50: 2nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta3 (27 to 718 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513980(CHEMBL4451803)
Affinity DataIC50: 2nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta3 (27 to 718 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513973(CHEMBL4458205)
Affinity DataIC50: 2.5nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta3 (27 to 718 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513967(CHEMBL4443365)
Affinity DataIC50: 3.20nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta3 (27 to 718 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513968(CHEMBL4461155)
Affinity DataIC50: 3.20nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta3 (27 to 718 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513977(CHEMBL4588580)
Affinity DataIC50: 3.20nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta3 (27 to 718 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513986(CHEMBL4557460)
Affinity DataIC50: 4nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta3 (27 to 718 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513972(CHEMBL4450454)
Affinity DataIC50: 4nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta3 (27 to 718 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513979(CHEMBL4543688)
Affinity DataIC50: 5nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta3 (27 to 718 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513984(CHEMBL4547961)
Affinity DataIC50: 5nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta3 (27 to 718 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513989(CHEMBL4529675)
Affinity DataIC50: 6.30nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta3 (27 to 718 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-6(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513974(CHEMBL4513624)
Affinity DataIC50: 6.30nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta6 (22 to 707 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513985(CHEMBL4518027)
Affinity DataIC50: 7.90nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta3 (27 to 718 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513982(CHEMBL4440801)
Affinity DataIC50: 7.90nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta3 (27 to 718 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513969(CHEMBL4435701)
Affinity DataIC50: 13nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta3 (27 to 718 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-6(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513988(CHEMBL4445933)
Affinity DataIC50: 13nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta6 (22 to 707 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-6(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513986(CHEMBL4557460)
Affinity DataIC50: 16nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta6 (22 to 707 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-6(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513968(CHEMBL4461155)
Affinity DataIC50: 20nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta6 (22 to 707 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-6(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513976(CHEMBL4539942)
Affinity DataIC50: 25nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta6 (22 to 707 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-6(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513967(CHEMBL4443365)
Affinity DataIC50: 32nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta6 (22 to 707 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-6(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513984(CHEMBL4547961)
Affinity DataIC50: 32nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta6 (22 to 707 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513978(CHEMBL4451540)
Affinity DataIC50: 40nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta3 (27 to 718 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-6(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513977(CHEMBL4588580)
Affinity DataIC50: 40nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta6 (22 to 707 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513987(CHEMBL4440536)
Affinity DataIC50: 50nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta3 (27 to 718 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-6(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513989(CHEMBL4529675)
Affinity DataIC50: 50nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta6 (22 to 707 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-6(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513972(CHEMBL4450454)
Affinity DataIC50: 63nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta6 (22 to 707 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-6(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513973(CHEMBL4458205)
Affinity DataIC50: 79nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta6 (22 to 707 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-6(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513985(CHEMBL4518027)
Affinity DataIC50: 79nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta6 (22 to 707 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-6(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513980(CHEMBL4451803)
Affinity DataIC50: 100nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta6 (22 to 707 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-6(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513966(CHEMBL4468875)
Affinity DataIC50: 126nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta6 (22 to 707 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513971(CHEMBL4450469)
Affinity DataIC50: 126nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta3 (27 to 718 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-6(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513979(CHEMBL4543688)
Affinity DataIC50: 158nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta6 (22 to 707 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513983(CHEMBL4471108)
Affinity DataIC50: 158nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta3 (27 to 718 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-6(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513982(CHEMBL4440801)
Affinity DataIC50: 251nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta6 (22 to 707 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-6(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513971(CHEMBL4450469)
Affinity DataIC50: 316nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta6 (22 to 707 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-6(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513969(CHEMBL4435701)
Affinity DataIC50: 398nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta6 (22 to 707 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-6(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513987(CHEMBL4440536)
Affinity DataIC50: 631nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta6 (22 to 707 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-6(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513983(CHEMBL4471108)
Affinity DataIC50: 794nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta6 (22 to 707 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-6(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513978(CHEMBL4451540)
Affinity DataIC50: 1.00E+3nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta6 (22 to 707 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-6(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513970(CHEMBL4557585)
Affinity DataIC50: 1.26E+3nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta6 (22 to 707 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513981(CHEMBL4592010)
Affinity DataIC50: 5.01E+3nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta3 (27 to 718 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-6(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513981(CHEMBL4592010)
Affinity DataIC50: 1.26E+4nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta6 (22 to 707 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513975(CHEMBL4483501)
Affinity DataIC50: 1.26E+4nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta3 (27 to 718 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-6(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50513975(CHEMBL4483501)
Affinity DataIC50: 1.95E+4nMAssay Description:Inhibition of recombinant human integrin alphaV (31 to 992 residues) beta6 (22 to 707 residues) expressed in CHO cells preincubated for 15 mins follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed